Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers

Cordoba, Abel; Escande, Alexandre; Leroy, T.; Mirabel, X.; Coche‐Dequeant, B.; Lartigau, Éric

doi:10.1016/j.brachy.2016.07.007

Cited by 8 publications

(41 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 shows a summary of studies included in this systematic review. Eight studies were single center studies [ 14 , 15 , 16 , 17 , 18 , 21 , 22 , 23 ] and 2 were multicentric studies [ 19 , 20 ].…”

Section: Resultsmentioning

confidence: 99%

“…Enrollment period of the studies were between 1970 and 2014. Study population and length of follow-up ranged from 47 to 221 patients and from 28.5 to 76.2 months, respectively [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. Histological types other than SCC classification according to the fourth edition of the World Health Organization [ 24 ] were included in 6 studies (range, 4.5-21.3%) [ 15 , 18 , 19 , 21 , 22 , 23 ].…”

Section: Resultsmentioning

confidence: 99%

“…In the earliest studies, EBRT was delivered by two-dimensional (2D) technique [ 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 ], while in the most recent series, 3D-conformal EBRT or intensity-modulated radiation therapy techniques were used [ 18 , 21 ]. The most frequent delivered dose was 45 Gy in 25 fractions [ 19 , 20 , 21 , 23 ]. The target volume was defined as anal region and pelvic nodes in all studies [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ], while inguinal nodes were included in 8 series [ 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 ].…”

Section: Resultsmentioning

confidence: 99%

“…The most frequent delivered dose was 45 Gy in 25 fractions [ 19 , 20 , 21 , 23 ]. The target volume was defined as anal region and pelvic nodes in all studies [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ], while inguinal nodes were included in 8 series [ 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 ]. CT was used either as neoadjuvant in 3 studies [ 17 , 20 , 21 ] or concomitant treatment in all studies [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Brachytherapy boost after chemoradiation in anal cancer: a systematic review

Frakulli

Buwenge

Cammelli

et al. 2018

jcb

View full text Add to dashboard Cite

Radio-chemotherapy (RCT) is the primary treatment of anal cancer (AC). However, the role and the optimal total dose of a radiation boost is still unclear. No randomized controlled trials nor systematic reviews have been performed to analyze the efficacy of brachytherapy (BRT) as boost in AC. Therefore, we performed this systematic review based on PRISMA methodology to establish the role of BRT boost in AC.A systematic search of the bibliographic databases: PubMed, Scopus, and Cochrane library from the earliest possible date through January 31, 2018 was performed. At least one of the following outcomes: local control (LC), loco-regional control (LRC), overall survival (OS), disease-free survival (DFS), or colostomy-free survival (CFS) had to be present for inclusion in this systematic review in patients receiving a BRT boost. Data about toxicity and sphincter function were also included.Ten articles fulfilled the inclusion criteria. All the studies had retrospective study design. All studies were classified to provide a level of evidence graded as 3 according to SIGN classification. Median 5-year LC/LRC, CFS, DFS, and OS were: 78.6% (range, 70.7-92.0%), 76.1% (range, 61.4-86.4%), 75.8% (range, 65.9-85.7%), and 69.4% (63.4-82.0%), respectively. The reported toxicities were acceptable.RCT is the treatment cornerstone in AC. High-level evidences from studies on BRT boost in AC are lacking. Further studies should investigate: efficacy of BRT boost in comparison to no boost and to external beam boost, patients who can benefit from this treatment intensification, and optimal radiation dose.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Brachytherapy boost after chemoradiation in anal cancer: a systematic review

Frakulli

Buwenge

Cammelli

et al. 2018

jcb

View full text Add to dashboard Cite

show abstract

“…The reported rate of FI following radiotherapy ranged, from 0 to 44% [18,[31][32][33][34][35][36][37][38][39][40][41][42]. Between 0.5 and 10.9% of anal cancer survivors were reported to have needed a colostomy due to severe anal sphincter dysfunction at a median follow-up of 32.4 months to 8.6 years [43][44][45][46][47][48][49][50][51].…”

Section: Fecal Incontinencementioning

confidence: 99%

Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review

et al. 2018

View full text Add to dashboard Cite

Introduction: There is a paucity of data on incidence and mechanisms of long-term gastrointestinal consequences after chemoradiotherapy for anal cancer. Most of the adverse effects reported were based on traditional external beam radiotherapy whilst only short-term follow-ups have been available for intensity-modulated radiotherapy, and there is lack of knowledge about consequences of doseescalation radiotherapy. Method: A systematic literature review. Results: Two thousand nine hundred and eighty-five titles (excluding duplicates) were identified through the search; 130 articles were included in this review. The overall incidence of late gastrointestinal toxicity was reported to be 7-64.5%, with Grade 3 and above (classified as severe) up to 33.3%. The most commonly reported late toxicities were fecal incontinence (up to 44%), diarrhea (up to 26.7%), and ulceration (up to 22.6%). Diarrhea, fecal incontinence and buttock pain were associated with lower scores in radiotherapy specific quality of life scales (QLQ-CR29, QLQ-C30, and QLQ-CR38) compared to healthy controls. Intensity-modulated radiation therapy appears to reduce late toxicity. Conclusion: Late gastrointestinal toxicities are common with severe toxicity seen in one-third of the patients. These symptoms significantly impact on patients' quality of life. Prospective studies with control groups are needed to elucidate long-term toxicity.

show abstract